{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T14:30:55Z","timestamp":1782311455228,"version":"3.54.5"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Natalizumab (NAT) is a high-efficacy treatment for relapsing remitting multiple sclerosis (RRMS). However, it is associated with an increased risk of progressive multifocal leukoencephalopathy that sometimes requires treatment cessation with a risk of returning disease activity. The aim of this study was to characterize the pharmacokinetics and -dynamics as well as neurodestruction marker serum neurofilament light chain (sNfL) in patients with RRMS and secondary progressive MS (SPMS) stopping NAT in correlation to clinical data.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> In this study, 50 RRMS and 9 SPMS patients after NAT cessation were included. Five RRMS patients on NAT treatment holiday were evaluated. Clinical and radiological disease activity were systemically assessed by frequent exams after NAT stop. Free NAT concentration, cell bound NAT, \u03b14-integrin expression and \u03b14-integrin-receptor saturation as well as immune cell frequencies were measured for up to 4 months after NAT withdrawal. Additionally, sNfL levels were observed up to 12 months in RRMS and up to 4 months in SPMS patients.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> NAT cessation was associated with a return of disease activity in 38% of the RRMS and 33% of the SPMS patients within 12 and 7 months, respectively. Concentration of free and cell bound NAT as well as \u03b14-integrin-receptor saturation decreased in the RRMS and SPMS patients whereas \u03b14-integrin expression increased over time. NAT induced increase of lymphocytes and its subsets normalized and a non-significant drop of NK and Th17 T-cells counts could be detected. All RRMS patients showed physiological sNfL levels &amp;lt;8pg\/ml 1 month after last NAT infusion. During follow-up period sNfL levels peaked up to 16-fold and were linked to return of disease activity in 19 of the 37 RRMS patients. Treatment holiday was also associated with a return of disease activity in 4 of 5 patients and with an increase of sNfL at an individual level.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> We demonstrate the reversibility of NAT pharmacodynamic and -kinetic markers. sNfL levels are associated with the recurrence of disease activity and can also serve as an early marker to predict present before onset of clinical or radiological disease activity on the individual level.<\/jats:p>","DOI":"10.3389\/fneur.2021.650530","type":"journal-article","created":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T05:31:17Z","timestamp":1618378277000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis"],"prefix":"10.3389","volume":"12","author":[{"given":"Undine","family":"Proschmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernan","family":"Inojosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Akg\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjalf","family":"Ziemssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1527-3458.2007.00003.x","article-title":"Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri\u00ae) in inflammatory diseases","volume":"13","author":"St\u00fcve","year":"2007","journal-title":"CNS Drug Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1212\/NXI.0000000000000388","article-title":"\u03b14-integrin receptor desaturation and disease activity return after natalizumab cessation","volume":"4","author":"Derfuss","year":"2017","journal-title":"Neurol Neuroimmunol Neuro."},{"key":"B4","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1017\/cjn.2019.42","article-title":"Clinical course of relapsing remitting multiple sclerosis post-natalizumab","volume":"46","author":"Fiander","year":"2019","journal-title":"Can J Neurol Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1007\/s00415-014-7325-8","article-title":"Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients","volume":"261","author":"Sorensen","year":"2014","journal-title":"J Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1136\/jnnp-2015-312221","article-title":"Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation","volume":"87","author":"Weinstock-Guttman","year":"2016","journal-title":"J Neurol Neuro Psychiatry."},{"key":"B7","doi-asserted-by":"publisher","first-page":"101498","DOI":"10.1016\/j.msard.2019.101498","article-title":"Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation","volume":"38","author":"Mustonen","year":"2020","journal-title":"Mul Scler Rel Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1136\/jnnp-2015-312940","article-title":"Extended interval dosing of natalizumab in multiple sclerosis","volume":"87","author":"Zhovtis Ryerson","year":"2016","journal-title":"J Neurol Neuro Psychiatry."},{"key":"B9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/1756285614540224","article-title":"Extended interval dosing of natalizumab: a two-center, 7-year experience","volume":"7","author":"Bomprezzi","year":"2014","journal-title":"Ther Adv Neurol Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00415-015-7655-1","article-title":"Body weight-based natalizumab treatment in adult patients with multiple sclerosis","volume":"262","author":"Tanaka","year":"2015","journal-title":"J Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.msard.2019.03.017","article-title":"Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing","volume":"31","author":"Foley","year":"2019","journal-title":"Mult Scl Rel Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13311-019-00776-7","article-title":"Extending the interval of natalizumab dosing: is efficacy preserved?","volume":"353","author":"Clerico","year":"2019","journal-title":"Neurotherapeutics."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e745","DOI":"10.1212\/WNL.0000000000009995","article-title":"Personalized extended interval dosing of natalizumab in MS: a prospective multicenter trial","volume":"95","author":"van Kempen","year":"2020","journal-title":"Neurology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3389\/fneur.2018.01071","article-title":"Real-world lab data in natalizumab treated multiple sclerosis patients up to 6 years long-term follow up","volume":"9","author":"Kaufmann","year":"2018","journal-title":"Front Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jns.2008.03.022","article-title":"The effects of natalizumab on the innate and adaptive immune system in the central nervous system","volume":"274","author":"St\u00fcve","year":"2008","journal-title":"J Neurol Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/1352458516640609","article-title":"Th17 cells: a prognostic marker for MS rebound after natalizumab cessation?","volume":"23","author":"Haas","year":"2017","journal-title":"Mul Scl J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1212\/WNL.0000000000004485","article-title":"Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients","volume":"89","author":"Plavina","year":"2017","journal-title":"Neurology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12974-016-0635-2","article-title":"New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies","volume":"13","author":"Sehr","year":"2016","journal-title":"J Neuro."},{"key":"B19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3389\/fimmu.2018.01560","article-title":"Immune cell profiling during switching from natalizumab to fingolimod reveals differential effects on systemic immune-regulatory networks and on trafficking of non-t cell populations into the cerebrospinal fluid\u2014results from the tofingo successor study","volume":"9","author":"Lohmann","year":"2018","journal-title":"Front Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1212\/WNL.0000000000003085","article-title":"Neurofilament light chain level is a weak risk factor for the development of MS","volume":"87","author":"Arrambide","year":"2016","journal-title":"Neurology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat Rev Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1093\/brain\/awy154","article-title":"Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis","volume":"141","author":"Barro","year":"2018","journal-title":"Brain."},{"key":"B23","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1177\/1352458515623365","article-title":"Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity","volume":"22","author":"Kuhle","year":"2016","journal-title":"Mul Scl J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1212\/WNL.0000000000003653","article-title":"Serum neurofilament is associated with progression of brain atrophy and disability in early MS","volume":"88","author":"Kuhle","year":"2017","journal-title":"Neurology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1177\/1352458519885613","article-title":"Neurofilament light levels are associated with long-term outcomes in multiple sclerosis:","volume":"26","author":"Kuhle","year":"2019","journal-title":"Mul Scl J."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","article-title":"Blood neurofilament light chain as a biomarker of MS disease activity and treatment response","volume":"92","author":"Kuhle","year":"2019","journal-title":"Neurology."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1201","DOI":"10.1212\/WNL.0000000000009097","article-title":"Blood neurofilament light levels segregate treatment effects in multiple sclerosis","volume":"94","author":"Delcoigne","year":"2020","journal-title":"Neurology."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e555","DOI":"10.1212\/NXI.0000000000000555","article-title":"Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS","volume":"6","author":"Akg\u00fcn","year":"2019","journal-title":"Neurol Neuroimmunol Neuro."},{"key":"B30","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/ana.25437","article-title":"Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients","volume":"85","author":"Dalla","year":"2019","journal-title":"Ann Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/ana.25523","article-title":"Serum neurofilaments as candidate biomarkers of natalizumab-associated PML","volume":"25","author":"Loonstra","year":"2019","journal-title":"Mul Scl J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","article-title":"Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension","volume":"17","author":"Kapoor","year":"2018","journal-title":"Lancet Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1212\/WNL.0000000000000355","article-title":"MS disease activity in RESTORE a randomized 24-week natalizumab treatment interruption study","volume":"82","author":"Fox","year":"2014","journal-title":"Neurology."},{"key":"B34","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1177\/2211068215589580","article-title":"The simoa HD-1 analyzer: a novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing","volume":"21","author":"Wilson","year":"2015","journal-title":"J Lab Auto."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1007\/s00415-011-5996-y","article-title":"De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate","volume":"258","author":"Havla","year":"2011","journal-title":"J Neurol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1212\/01.wnl.0000265393.03231.e5","article-title":"Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients","volume":"70","author":"Vellinga","year":"2008","journal-title":"Neurology."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1136\/jnnp-2014-307591","article-title":"Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis","volume":"85","author":"Gueguen","year":"2014","journal-title":"J Neurol Neuro Psychiatry."},{"key":"B38","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s00415-014-7558-6","article-title":"Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE","volume":"262","author":"Kaufman","year":"2014","journal-title":"J Neurol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jns.2011.05.043","article-title":"Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients","volume":"308","author":"Kerbrat","year":"2011","journal-title":"J Neurol Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1001\/archneurol.2010.257","article-title":"Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy","volume":"68","author":"Miravalle","year":"2011","journal-title":"Arch Neurol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/ana.22074","article-title":"Natalizumab drug holiday in multiple sclerosis: poorly tolerated","volume":"68","author":"Killestein","year":"2010","journal-title":"Ann Neurol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1177\/1352458516641775","article-title":"Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal:","volume":"23","author":"Larochelle","year":"2016","journal-title":"Mul Scl J."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1756286419837809","DOI":"10.1177\/1756286419837809","article-title":"Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis:","volume":"12","author":"Prosperini","year":"2019","journal-title":"Ther Adv Neurol Dis."},{"key":"B44","volume-title":"Characteristics of PML Cases in Multiple Sclerosis Patients Switching to Fingolimod From Natalizumab","author":"Putzki","year":"2014"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/307872","article-title":"PML-IRIS during fingolimod diagnosed after natalizumab discontinuation","volume":"2014","author":"Killestein","year":"2014","journal-title":"Case Rep Neurol Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1136\/practneurol-2015-001355","article-title":"Switching patients at high risk of PML from natalizumab to another disease-modifying therapy","volume":"16","author":"Giovannoni","year":"2016","journal-title":"Pract Neurol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40893-016-0011-1","article-title":"Hands on alemtuzumab-experience from clinical practice: whom and how to treat","volume":"1","author":"Hassoun","year":"2016","journal-title":"Mul Scl Dem Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/ana.24651","article-title":"Rituximab versus fingolimod after natalizumab in multiple sclerosis patients","volume":"79","author":"Alping","year":"2016","journal-title":"Ann Neurol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00415-018-9117-z","article-title":"Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation","volume":"266","author":"Pfeuffer","year":"2019","journal-title":"J Neurol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1177\/1352458520946017","article-title":"Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab:","volume":"27","author":"Mancinelli","year":"2020","journal-title":"Mul Scl J"},{"key":"B51","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/eji.201142108","article-title":"Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis","volume":"42","author":"Planas","year":"2012","journal-title":"Eur J Immunol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e3319","DOI":"10.1371\/journal.pone.0003319","article-title":"Effects of natalizumab treatment on Foxp3+ T regulatory cells","volume":"3","author":"Stenner","year":"2008","journal-title":"PLoS ONE."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1093\/brain\/awy069","article-title":"T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention","volume":"141","author":"van Langelaar","year":"2018","journal-title":"Brain."},{"key":"B54","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/ana.22247","article-title":"Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab","volume":"69","author":"Gunnarsson","year":"2011","journal-title":"Ann Neurol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1111\/ane.12151","article-title":"Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis","volume":"128","author":"Kuhle","year":"2013","journal-title":"Acta Neurol Scand."},{"key":"B56","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.msard.2018.06.015","article-title":"Efficacy and safety of natalizumab extended interval dosing","volume":"24","author":"Yamout","year":"2018","journal-title":"Mul Scl Rel Dis."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.650530\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T05:31:21Z","timestamp":1618378281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.650530\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,14]]},"references-count":56,"alternative-id":["10.3389\/fneur.2021.650530"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.650530","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,14]]},"article-number":"650530"}}